{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:11:51Z","timestamp":1780791111250,"version":"3.54.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BU 1141\/13-1"],"award-info":[{"award-number":["BU 1141\/13-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Proprotein convertase subtilisin\/kexin type 9 (PCSK9) is of particular importance in cholesterol metabolism with high levels contributing to hypercholesterolemia. Cholesterol and sphingolipids are low in patients with liver cirrhosis. Purpose of this study was to find associations of plasma PCSK9 with circulating cholesterol and sphingolipid species and measures of liver disease severity in patients with liver cirrhosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PCSK9 protein levels were determined by ELISA in systemic vein (SVP), hepatic vein (HVP) and portal vein plasma of patients with mostly alcoholic liver cirrhosis. PCSK9 and LDL-receptor protein expression were analysed in cirrhotic and non-cirrhotic liver tissues.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Serum PCSK9 was reduced in patients with liver cirrhosis in comparison to non-cirrhotic patients. In liver cirrhosis, plasma PCSK9 was not correlated with Child-Pugh score, Model for End-Stage Liver Disease score, bilirubin or aminotransferases. A negative association of SVP PCSK9 with albumin existed. PCSK9 protein in the liver did not change with fibrosis stage and was even positively correlated with LDL-receptor protein levels. Ascites volume and variceal size were not related to PCSK9 levels. Along the same line, transjugular intrahepatic shunt to lower portal pressure did not affect PCSK9 concentrations in the three blood compartments. Serum cholesterol, sphingomyelin and ceramide levels did not correlate with PCSK9. Stratifying patients by high versus low PCSK9 levels using the median as cut-off, several cholesteryl ester species were even low in the subgroup with high PCSK9 levels. A few sphingomyelin species were also reduced in the patients with PCSK9 levels above the median. PCSK9 is highly expressed in the liver but systemic, portal and hepatic vein levels were similar. PCSK9 was not correlated with the inflammatory proteins C-reactive protein, IL-6, galectin-3, resistin or pentraxin 3. Of note, HVP PCSK9 was positively associated with HVP chemerin and negatively with HVP adiponectin levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In the cohort of patients with liver cirrhosis mostly secondary to alcohol consumption high PCSK9 was associated with low levels of certain cholesteryl ester and sphingomyelin species. Positive correlations of PCSK9 and LDL-receptor protein in the liver of patients with chronic liver injury are consistent with these findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-021-01431-x","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T15:02:50Z","timestamp":1610982170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Proprotein convertase subtilisin\/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis"],"prefix":"10.1186","volume":"20","author":[{"given":"Susanne","family":"Feder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Wiest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Aslanidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Schacherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Krautbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Liebisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-3994","authenticated-orcid":false,"given":"Christa","family":"Buechler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,18]]},"reference":[{"key":"1431_CR1","first-page":"85","volume":"110","author":"J Wiegand","year":"2013","unstructured":"Wiegand J, Berg T. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int. 2013;110:85\u201391.","journal-title":"Dtsch Arztebl Int"},{"key":"1431_CR2","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.3748\/wjg.v20.i18.5442","volume":"20","author":"S Nusrat","year":"2014","unstructured":"Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014;20:5442\u201360.","journal-title":"World J Gastroenterol"},{"key":"1431_CR3","doi-asserted-by":"publisher","first-page":"e2877","DOI":"10.1097\/MD.0000000000002877","volume":"95","author":"Y Peng","year":"2016","unstructured":"Peng Y, Qi X, Guo X. Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies. Medicine (Baltimore). 2016;95:e2877.","journal-title":"Medicine (Baltimore)"},{"key":"1431_CR4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/BF01537534","volume":"61","author":"C Breier","year":"1983","unstructured":"Breier C, Lisch HJ, Braunsteiner H. Lipoproteins, HDL-apolipoproteins, activities of hepatic lipase and lecithin-cholesterol acyltransferase in the plasma of patients with post-alcoholic end-stage liver cirrhosis. Klin Wochenschr. 1983;61:929\u201331.","journal-title":"Klin Wochenschr"},{"key":"1431_CR5","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1001\/archinte.1997.00440280120012","volume":"157","author":"C Cicognani","year":"1997","unstructured":"Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med. 1997;157:792\u20136.","journal-title":"Arch Intern Med"},{"key":"1431_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1159\/000339206","volume":"21","author":"CC Vere","year":"2012","unstructured":"Vere CC, Streba CT, Streba L, Rogoveanu I. Lipid serum profile in patients with viral liver cirrhosis. Med Princ Pract. 2012;21:566\u20138.","journal-title":"Med Princ Pract"},{"key":"1431_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1194\/jlr.D800028-JLR200","volume":"50","author":"P Wiesner","year":"2009","unstructured":"Wiesner P, Leidl K, Boettcher A, Schmitz G, Liebisch G. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res. 2009;50:574\u201385.","journal-title":"J Lipid Res"},{"key":"1431_CR8","first-page":"158658","volume":"2020","author":"C Buechler","year":"1865","unstructured":"Buechler C, Aslanidis C. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma. Biochim Biophys Acta Mol Cell Biol Lipids. 1865;2020:158658.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"1431_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10238-013-0262-5","volume":"14","author":"L Chrostek","year":"2014","unstructured":"Chrostek L, Supronowicz L, Panasiuk A, Cylwik B, Gruszewska E, Flisiak R. The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins. Clin Exp Med. 2014;14:417\u201321.","journal-title":"Clin Exp Med"},{"key":"1431_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/biof.1619","volume":"46","author":"A Cesaro","year":"2020","unstructured":"Cesaro A, Bianconi V, Gragnano F, Moscarella E, Fimiani F, Monda E, Scudiero O, Limongelli G, Pirro M, Calabro P. Beyond cholesterol metabolism: the pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. Biofactors. 2020;46:367\u201380.","journal-title":"Biofactors."},{"key":"1431_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1365-2796.2009.02167.x","volume":"266","author":"SA Mousavi","year":"2009","unstructured":"Mousavi SA, Berge KE, Leren TP. The unique role of proprotein convertase subtilisin\/kexin 9 in cholesterol homeostasis. J Intern Med. 2009;266:507\u201319.","journal-title":"J Intern Med"},{"key":"1431_CR12","first-page":"158792","volume":"2020","author":"MR Emma","year":"1865","unstructured":"Emma MR, Giannitrapani L, Cabibi D, Porcasi R, Pantuso G, Augello G, Giglio RV, Re NL, Capitano AR, Montalto G, et al. Hepatic and circulating levels of PCSK9 in morbidly obese patients: relation with severity of liver steatosis. Biochim Biophys Acta Mol Cell Biol Lipids. 1865;2020:158792.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"1431_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clinbiochem.2020.01.003","volume":"77","author":"M Paquette","year":"2020","unstructured":"Paquette M, Gauthier D, Chamberland A, Prat A, De Lucia RE, Rasmussen JJ, Kaduka L, Seidah NG, Bernard S, Christensen DL, Baass A. Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis. Clin Biochem. 2020;77:20\u20135.","journal-title":"Clin Biochem"},{"key":"1431_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2018.09.008","volume":"278","author":"M Wargny","year":"2018","unstructured":"Wargny M, Ducluzeau PH, Petit JM, Le May C, Smati S, Arnaud L, Pichelin M, Bouillet B, Lannes A, Blanchet O, et al. Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. Atherosclerosis. 2018;278:82\u201390.","journal-title":"Atherosclerosis."},{"key":"1431_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","volume":"5","author":"AA Momtazi-Borojeni","year":"2019","unstructured":"Momtazi-Borojeni AA, Sabouri-Rad S, Gotto AM, Pirro M, Banach M, Awan Z, Barreto GE, Sahebkar A. PCSK9 and inflammation: a review of experimental and clinical evidence. Eur Heart J Cardiovasc Pharmacother. 2019;5:237\u201345.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1431_CR16","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","volume":"8","author":"C Ricci","year":"2018","unstructured":"Ricci C, Ruscica M, Camera M, Rossetti L, Macchi C, Colciago A, Zanotti I, Lupo MG, Adorni MP, Cicero AFG, et al. PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep. 2018;8:2267.","journal-title":"Sci Rep"},{"key":"1431_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","volume":"262","author":"ZH Tang","year":"2017","unstructured":"Tang ZH, Peng J, Ren Z, Yang J, Li TT, Li TH, Wang Z, Wei DH, Liu LS, Zheng XL, Jiang ZS. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-kappaB pathway. Atherosclerosis. 2017;262:113\u201322.","journal-title":"Atherosclerosis."},{"key":"1431_CR18","doi-asserted-by":"crossref","unstructured":"Lei L, Li X, Yuan YJ, Chen ZL, He JH, Wu JH, Cai XS. Inhibition of proprotein convertase subtilisin\/kexin type 9 attenuates 2,4,6-trinitrobenzenesulfonic acid-induced colitis via repressing toll-like receptor 4\/nuclear factor-kappa B. Kaohsiung J Med Sci. 2020:1\u20137.","DOI":"10.1002\/kjm2.12225"},{"key":"1431_CR19","doi-asserted-by":"publisher","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","volume":"6","author":"KR Walley","year":"2014","unstructured":"Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, Christie JD, Nakada TA, Fjell CD, Thair SA, et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med. 2014;6:258ra143.","journal-title":"Sci Transl Med"},{"key":"1431_CR20","doi-asserted-by":"crossref","unstructured":"Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C. Adipokines in liver cirrhosis. Int J Mol Sci. 2017;18.","DOI":"10.3390\/ijms18071392"},{"key":"1431_CR21","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.cgh.2017.09.017","volume":"16","author":"J RemmLer","year":"2018","unstructured":"RemmLer J, Schneider C, Treuner-Kaueroff T, Bartels M, Seehofer D, Scholz M, Berg T, Kaiser T. Increased level of interleukin 6 associates with increased 90-day and 1-year mortality in patients with end-stage liver disease. Clin Gastroenterol Hepatol. 2018;16:730\u20137.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1431_CR22","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/1750-3841.13647","volume":"82","author":"Y Cai","year":"2017","unstructured":"Cai Y, Lu D, Zou Y, Zhou C, Liu H, Tu C, Li F, Liu L, Zhang S. Curcumin protects against intestinal origin Endotoxemia in rat liver cirrhosis by targeting PCSK9. J Food Sci. 2017;82:772\u201380.","journal-title":"J Food Sci"},{"key":"1431_CR23","doi-asserted-by":"publisher","first-page":"17167","DOI":"10.1038\/s41598-019-53603-6","volume":"9","author":"JS Lee","year":"2019","unstructured":"Lee JS, Mukhopadhyay P, Matyas C, Trojnar E, Paloczi J, Yang YR, Blank BA, Savage C, Sorokin AV, Mehta NN, et al. PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease. Sci Rep. 2019;9:17167.","journal-title":"Sci Rep"},{"key":"1431_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181540","volume":"12","author":"V Schlegel","year":"2017","unstructured":"Schlegel V, Treuner-Kaueroff T, Seehofer D, Berg T, Becker S, Ceglarek U, Thiery J, Kaiser T. Low PCSK9 levels are correlated with mortality in patients with end-stage liver disease. PLoS One. 2017;12:e0181540.","journal-title":"PLoS One"},{"key":"1431_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12876-015-0371-6","volume":"15","author":"M Bhat","year":"2015","unstructured":"Bhat M, Skill N, Marcus V, Deschenes M, Tan X, Bouteaud J, Negi S, Awan Z, Aikin R, Kwan J, et al. Decreased PCSK9 expression in human hepatocellular carcinoma. BMC Gastroenterol. 2015;15:176.","journal-title":"BMC Gastroenterol"},{"key":"1431_CR26","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.atherosclerosis.2013.03.029","volume":"228","author":"MT Janis","year":"2013","unstructured":"Janis MT, Tarasov K, Ta HX, Suoniemi M, Ekroos K, Hurme R, Lehtimaki T, Paiva H, Kleber ME, Marz W, et al. Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin\/kexin type 9 (PCSK9) deficiency. Atherosclerosis. 2013;228:380\u20135.","journal-title":"Atherosclerosis."},{"key":"1431_CR27","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1194\/jlr.D008532","volume":"51","author":"SM Hammad","year":"2010","unstructured":"Hammad SM, Pierce JS, Soodavar F, Smith KJ, Al Gadban MM, Rembiesa B, Klein RL, Hannun YA, Bielawski J, Bielawska A. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J Lipid Res. 2010;51:3074\u201387.","journal-title":"J Lipid Res"},{"key":"1431_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.atherosclerosis.2018.01.004","volume":"269","author":"M Hilvo","year":"2018","unstructured":"Hilvo M, Simolin H, Metso J, Ruuth M, Oorni K, Jauhiainen M, Laaksonen R, Baruch A. PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions. Atherosclerosis. 2018;269:159\u201365.","journal-title":"Atherosclerosis."},{"key":"1431_CR29","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/hep.22354","volume":"48","author":"A Zaid","year":"2008","unstructured":"Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, et al. Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008;48:646\u201354.","journal-title":"Hepatology."},{"key":"1431_CR30","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/gut.2009.193227","volume":"59","author":"M Rossle","year":"2010","unstructured":"Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59:988\u20131000.","journal-title":"Gut."},{"key":"1431_CR31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.yexmp.2015.01.010","volume":"98","author":"K Eisinger","year":"2015","unstructured":"Eisinger K, Krautbauer S, Wiest R, Weiss TS, Buechler C. Reduced serum chemerin in patients with more severe liver cirrhosis. Exp Mol Pathol. 2015;98:208\u201313.","journal-title":"Exp Mol Pathol"},{"key":"1431_CR32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.cyto.2011.06.001","volume":"55","author":"J Wanninger","year":"2011","unstructured":"Wanninger J, Weigert J, Wiest R, Bauer S, Karrasch T, Farkas S, Scherer MN, Walter R, Weiss TS, Hellerbrand C, et al. Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. Cytokine. 2011;55:435\u201340.","journal-title":"Cytokine."},{"key":"1431_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10238-020-00617-4","volume":"20","author":"S Feder","year":"2020","unstructured":"Feder S, Haberl EM, Spirk M, Weiss TS, Wiest R, Buechler C. Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients. Clin Exp Med. 2020;20:289\u201397.","journal-title":"Clin Exp Med"},{"key":"1431_CR34","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.metabol.2009.09.011","volume":"59","author":"R Wiest","year":"2010","unstructured":"Wiest R, Moleda L, Farkas S, Scherer M, Kopp A, Wonckhaus U, Buchler C, Scholmerich J, Schaffler A. Splanchnic concentrations and postprandial release of visceral adipokines. Metabolism. 2010;59:664\u201370.","journal-title":"Metabolism."},{"key":"1431_CR35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cyto.2010.06.013","volume":"53","author":"R Wiest","year":"2011","unstructured":"Wiest R, Weigert J, Wanninger J, Neumeier M, Bauer S, Schmidhofer S, Farkas S, Scherer MN, Schaffler A, Scholmerich J, Buechler C. Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis. Cytokine. 2011;53:178\u201383.","journal-title":"Cytokine."},{"key":"1431_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.prostaglandins.2017.06.004","volume":"131","author":"S Krautbauer","year":"2017","unstructured":"Krautbauer S, Wiest R, Liebisch G, Buechler C. Associations of systemic sphingolipids with measures of hepatic function in liver cirrhosis are related to cholesterol. Prostaglandins Other Lipid Mediat. 2017;131:25\u201332.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"1431_CR37","doi-asserted-by":"crossref","unstructured":"Haberl EM, Feder S, Pohl R, Rein-Fischboeck L, Durholz K, Eichelberger L, Wanninger J, Weiss TS, Buechler C. Chemerin Is Induced in Non-Alcoholic Fatty Liver Disease and Hepatitis B-Related Hepatocellular Carcinoma. Cancers (Basel). 2020;12.","DOI":"10.3390\/cancers12102967"},{"key":"1431_CR38","first-page":"121","volume":"2006","author":"G Liebisch","year":"1761","unstructured":"Liebisch G, Binder M, Schifferer R, Langmann T, Schulz B, Schmitz G. High throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem mass spectrometry (ESI-MS\/MS). Biochim Biophys Acta. 1761;2006:121\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"1431_CR39","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/S0022-2275(20)33398-8","volume":"40","author":"G Liebisch","year":"1999","unstructured":"Liebisch G, Drobnik W, Reil M, Trumbach B, Arnecke R, Olgemoller B, Roscher A, Schmitz G. Quantitative measurement of different ceramide species from crude cellular extracts by electrospray ionization tandem mass spectrometry (ESI-MS\/MS). J Lipid Res. 1999;40:1539\u201346.","journal-title":"J Lipid Res"},{"key":"1431_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jchromb.2011.10.037","volume":"883\u2013884","author":"G Liebisch","year":"2012","unstructured":"Liebisch G, Scherer M. Quantification of bioactive sphingo- and glycerophospholipid species by electrospray ionization tandem mass spectrometry in blood. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;883\u2013884:141\u20136.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1431_CR41","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"1431_CR42","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/gut.52.6.879","volume":"52","author":"B Angermayr","year":"2003","unstructured":"Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, Mendel H, Pichler L, Wichlas M, Kreil A, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut. 2003;52:879\u201385.","journal-title":"Gut."},{"key":"1431_CR43","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1007\/s10620-006-9310-2","volume":"51","author":"M Wadhawan","year":"2006","unstructured":"Wadhawan M, Dubey S, Sharma BC, Sarin SK. Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child's status. Dig Dis Sci. 2006;51:2264\u20139.","journal-title":"Dig Dis Sci"},{"key":"1431_CR44","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jhep.2010.09.020","volume":"54","author":"C Iacobini","year":"2011","unstructured":"Iacobini C, Menini S, Ricci C, Fantauzzi CB, Scipioni A, Salvi L, Cordone S, Delucchi F, Serino M, Federici M, et al. Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. J Hepatol. 2011;54:975\u201383.","journal-title":"J Hepatol"},{"key":"1431_CR45","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1055\/s-2007-985897","volume":"39","author":"MA Lazar","year":"2007","unstructured":"Lazar MA. Resistin- and obesity-associated metabolic diseases. Horm Metab Res. 2007;39:710\u20136.","journal-title":"Horm Metab Res"},{"key":"1431_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10875-007-9126-7","volume":"28","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008;28:1\u201313.","journal-title":"J Clin Immunol"},{"key":"1431_CR47","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.tem.2010.08.001","volume":"21","author":"MC Ernst","year":"2010","unstructured":"Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010;21:660\u20137.","journal-title":"Trends Endocrinol Metab"},{"key":"1431_CR48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.yexmp.2013.07.009","volume":"95","author":"S Krautbauer","year":"2013","unstructured":"Krautbauer S, Wanninger J, Eisinger K, Hader Y, Beck M, Kopp A, Schmid A, Weiss TS, Dorn C, Buechler C. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver. Exp Mol Pathol. 2013;95:199\u2013205.","journal-title":"Exp Mol Pathol"},{"key":"1431_CR49","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1365-2265.2009.03664.x","volume":"72","author":"J Weigert","year":"2010","unstructured":"Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, Farkas S, Scherer MN, Schaffler A, Aslanidis C, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf). 2010;72:342\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1431_CR50","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1373\/clinchem.2007.099747","volume":"54","author":"G Lambert","year":"2008","unstructured":"Lambert G, Ancellin N, Charlton F, Comas D, Pilot J, Keech A, Patel S, Sullivan DR, Cohn JS, Rye KA, Barter PJ. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem. 2008;54:1038\u201345.","journal-title":"Clin Chem"},{"key":"1431_CR51","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1128\/JVI.02727-13","volume":"88","author":"GH Syed","year":"2014","unstructured":"Syed GH, Tang H, Khan M, Hassanein T, Liu J, Siddiqui A. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J Virol. 2014;88:2519\u201329.","journal-title":"J Virol"},{"key":"1431_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/hep.22911","volume":"50","author":"P Labonte","year":"2009","unstructured":"Labonte P, Begley S, Guevin C, Asselin MC, Nassoury N, Mayer G, Prat A, Seidah NG. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology. 2009;50:17\u201324.","journal-title":"Hepatology."},{"key":"1431_CR53","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1111\/jcmm.13273","volume":"21","author":"M Pirro","year":"2017","unstructured":"Pirro M, Bianconi V, Francisci D, Schiaroli E, Bagaglia F, Sahebkar A, Baldelli F. Hepatitis C virus and proprotein convertase subtilisin\/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism. J Cell Mol Med. 2017;21:3150\u201361.","journal-title":"J Cell Mol Med"},{"key":"1431_CR54","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12933-019-0949-3","volume":"18","author":"C Caselli","year":"2019","unstructured":"Caselli C, Del Turco S, Ragusa R, Lorenzoni V, De Graaf M, Basta G, Scholte A, De Caterina R, Neglia D. Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. Cardiovasc Diabetol. 2019;18:144.","journal-title":"Cardiovasc Diabetol"},{"key":"1431_CR55","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3803\/EnM.2020.35.2.480","volume":"35","author":"E Han","year":"2020","unstructured":"Han E, Cho NH, Moon SS, Cho H. Comparison of Serum PCSK9 Levels in Subjects with Normoglycemia, Impaired Fasting Glucose, and Impaired Glucose Tolerance. Endocrinol Metab (Seoul). 2020;35:480\u20133.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"1431_CR56","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2217\/clp.13.55","volume":"8","author":"J Liu","year":"2013","unstructured":"Liu J, Guo YL, Xu RX, Li JJ. Rapid effects of different lipid-lowering drugs on PCSK9 in humans. Clinical Lipidology. 2013;8:519\u201324.","journal-title":"Clinical Lipidology"},{"key":"1431_CR57","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1194\/jlr.M049346","volume":"55","author":"B Han","year":"2014","unstructured":"Han B, Eacho PI, Knierman MD, Troutt JS, Konrad RJ, Yu X, Schroeder KM. Isolation and characterization of the circulating truncated form of PCSK9. J Lipid Res. 2014;55:1505\u201314.","journal-title":"J Lipid Res"},{"key":"1431_CR58","doi-asserted-by":"publisher","first-page":"11597","DOI":"10.3748\/wjg.v21.i41.11597","volume":"21","author":"M Usami","year":"2015","unstructured":"Usami M, Miyoshi M, Yamashita H. Gut microbiota and host metabolism in liver cirrhosis. World J Gastroenterol. 2015;21:11597\u2013608.","journal-title":"World J Gastroenterol"},{"key":"1431_CR59","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10753-019-01114-x","volume":"43","author":"Y Zou","year":"2020","unstructured":"Zou Y, Li S, Xu B, Guo H, Zhang S, Cai Y. Inhibition of Proprotein Convertase Subtilisin\/Kexin type 9 ameliorates liver fibrosis via mitigation of intestinal Endotoxemia. Inflammation. 2020;43:251\u201363.","journal-title":"Inflammation."},{"key":"1431_CR60","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1161\/ATVBAHA.120.314194","volume":"40","author":"D Garcon","year":"2020","unstructured":"Garcon D, Moreau F, Ayer A, Dijk W, Prieur X, Arnaud L, Roubtsova A, Seidah N, Prat A, Cariou B, Le May C. Circulating rather than intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin type 9) regulates postprandial Lipemia in mice. Arterioscler Thromb Vasc Biol. 2020;40:2084\u201394.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1431_CR61","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.4254\/wjh.v7.i16.1974","volume":"7","author":"M Dirchwolf","year":"2015","unstructured":"Dirchwolf M, Ruf AE. Role of systemic inflammation in cirrhosis: from pathogenesis to prognosis. World J Hepatol. 2015;7:1974\u201381.","journal-title":"World J Hepatol"},{"key":"1431_CR62","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.023","volume":"374","author":"KR Feingold","year":"2008","unstructured":"Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C. Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun. 2008;374:341\u20134.","journal-title":"Biochem Biophys Res Commun"},{"key":"1431_CR63","first-page":"2801","volume":"17","author":"C Buechler","year":"2011","unstructured":"Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol. 2011;17:2801\u201311.","journal-title":"World J Gastroenterol"},{"key":"1431_CR64","doi-asserted-by":"crossref","unstructured":"Feder S, Bruckmann A, McMullen N, Sinal CJ, Buechler C. Chemerin isoform-specific effects on hepatocyte migration and immune cell inflammation. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21197205"},{"key":"1431_CR65","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/oby.22871","volume":"28","author":"J Fischer","year":"2020","unstructured":"Fischer J, Volzke H, Kassubek J, Muller HP, Kuhn JP, Nauck M, Friedrich N, Zylla S. Associations of a panel of Adipokines with fat deposits and metabolic phenotypes in a general population. Obesity (Silver Spring). 2020;28:1550\u20139.","journal-title":"Obesity (Silver Spring)"},{"key":"1431_CR66","doi-asserted-by":"publisher","first-page":"9242","DOI":"10.1038\/s41598-018-27543-6","volume":"8","author":"P Horn","year":"2018","unstructured":"Horn P, von Loeffelholz C, Forkert F, Stengel S, Reuken P, Aschenbach R, Stallmach A, Bruns T. Low circulating chemerin levels correlate with hepatic dysfunction and increased mortality in decompensated liver cirrhosis. Sci Rep. 2018;8:9242.","journal-title":"Sci Rep"},{"key":"1431_CR67","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1194\/jlr.M800027-JLR200","volume":"49","author":"A Grefhorst","year":"2008","unstructured":"Grefhorst A, McNutt MC, Lagace TA, Horton JD. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res. 2008;49:1303\u201311.","journal-title":"J Lipid Res"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01431-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-021-01431-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01431-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T06:05:29Z","timestamp":1674885929000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01431-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1431"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01431-x","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,18]]},"assertion":[{"value":"8 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The manuscript or parts of it were not published or submitted elsewhere. The study was performed according to the updated guidelines of good clinical practice and Declaration of Helsinki. Informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}